Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 46.37 billion. The enterprise value is 163.46 billion.
| Market Cap | 46.37B |
| Enterprise Value | 163.46B |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jun 23, 2026 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -1.37% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 27.64% |
| Float | 1.27B |
Valuation Ratios
The trailing PE ratio is 5.67 and the forward PE ratio is 5.17. Sinopharm Group's PEG ratio is 1.77.
| PE Ratio | 5.67 |
| Forward PE | 5.17 |
| PS Ratio | 0.07 |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | 1.74 |
| P/OCF Ratio | 1.64 |
| PEG Ratio | 1.77 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.49, with an EV/FCF ratio of 6.15.
| EV / Earnings | 19.96 |
| EV / Sales | 0.25 |
| EV / EBITDA | 6.49 |
| EV / EBIT | 7.87 |
| EV / FCF | 6.15 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.40 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.93 |
| Debt / FCF | 3.53 |
| Interest Coverage | 8.30 |
Financial Efficiency
Return on equity (ROE) is 8.04% and return on invested capital (ROIC) is 6.83%.
| Return on Equity (ROE) | 8.04% |
| Return on Assets (ROA) | 2.55% |
| Return on Invested Capital (ROIC) | 6.83% |
| Return on Capital Employed (ROCE) | 11.52% |
| Weighted Average Cost of Capital (WACC) | 3.43% |
| Revenue Per Employee | 7.30M |
| Profits Per Employee | 90,538 |
| Employee Count | 90,447 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 7.97 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.45 billion in taxes.
| Income Tax | 4.45B |
| Effective Tax Rate | 26.54% |
Stock Price Statistics
The stock price has decreased by -19.02% in the last 52 weeks. The beta is 0.44, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -19.02% |
| 50-Day Moving Average | 16.12 |
| 200-Day Moving Average | 18.50 |
| Relative Strength Index (RSI) | 32.93 |
| Average Volume (20 Days) | 4,998,970 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 660.27 billion and earned 8.19 billion in profits. Earnings per share was 2.62.
| Revenue | 660.27B |
| Gross Profit | 46.64B |
| Operating Income | 19.46B |
| Pretax Income | 16.78B |
| Net Income | 8.19B |
| EBITDA | 21.72B |
| EBIT | 19.46B |
| Earnings Per Share (EPS) | 2.62 |
Balance Sheet
The company has 35.84 billion in cash and 93.88 billion in debt, with a net cash position of -58.04 billion or -18.60 per share.
| Cash & Cash Equivalents | 35.84B |
| Total Debt | 93.88B |
| Net Cash | -58.04B |
| Net Cash Per Share | -18.60 |
| Equity (Book Value) | 157.40B |
| Book Value Per Share | 31.52 |
| Working Capital | 119.06B |
Cash Flow
In the last 12 months, operating cash flow was 28.27 billion and capital expenditures -1.68 billion, giving a free cash flow of 26.59 billion.
| Operating Cash Flow | 28.27B |
| Capital Expenditures | -1.68B |
| Depreciation & Amortization | 2.29B |
| Net Borrowing | -26.85B |
| Free Cash Flow | 26.59B |
| FCF Per Share | 8.52 |
Margins
Gross margin is 7.06%, with operating and profit margins of 2.95% and 1.24%.
| Gross Margin | 7.06% |
| Operating Margin | 2.95% |
| Pretax Margin | 2.54% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.29% |
| EBIT Margin | 2.95% |
| FCF Margin | 3.97% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 5.42%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 5.42% |
| Dividend Growth (YoY) | 6.90% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 29.92% |
| FCF Payout Ratio | 9.27% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.42% |
| Earnings Yield | 17.66% |
| FCF Yield | 57.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sinopharm Group is 21.10, which is 41.99% higher than the current price. The consensus rating is "Buy".
| Price Target | 21.10 |
| Price Target Difference | 41.99% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 3.13% |
| EPS Growth Forecast (3Y) | 6.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.19 |
| Piotroski F-Score | 7 |